CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03380962
Title field or adapter rule: {'original_value': 'A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T01:06:25.611245+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Results Posted At: 2026-10-30
Source Retrieved At: 2026-10-31T01:06:25.053101+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Kidney Failure, Chronic", "End-Stage Renal Disease", "Transplant Glomerulopathy", "Transplant;Failure,Kidney", "Kidney Transplant Failure and Rejection", "Antibody-mediated Rejection", "Kidney Transplant; Complications"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT03380962"
protocolSection.identificationModule.officialTitle: "A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}

{'armGroupLabels': ['Clazakizumab'], 'description': 'All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.', 'name': 'Clazakizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.